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Abstract
Induction TPF regimen is a standard treatment option for squamous cell carci-
noma (SCC) of the oropharynx. The efficacy and safety of adding cetuximab to
induction TPF (ETPF) therapy was evaluated. Patients with nonmetastatic
resectable stage III/IV SCC of the oropharynx were treated with weekly cetux-
imab followed the same day by docetaxel and cisplatin and by a continuous
infusion of 5-fluorouracil on days 1-5 (every 3 weeks, 3 cycles). The primary
endpoint was clinical and radiological complete response (crCR) of primary
tumor at 3 months. Secondary endpoints were crCR rates, overall response,
pathological CR, progression-free survival, overall survival, and safety. Forty-
two patients were enrolled, and 41 received ETPF. The all nine planned cetux-
imab doses and the full three doses of planned chemotherapy were completed
in 31 (76%) and 36 (88%) patients, respectively. Twelve (29%) patients
required dose reduction. The crCR of primary tumor at the completion of ther-
apy was observed in nine (22%) patients. ETPF was associated with a tumor
objective response rate (ORR) of 58%. The most frequent grade 3–4 toxicities
were as follows: nonfebrile neutropenia (39%), febrile neutropenia (19%),
diarrhea (10%), and stomatitis (12%). Eighteen (44%) patients experienced
acne-like skin reactions of any grade. One toxic death occurred secondary to
chemotherapy-induced colitis with colonic perforation. This phase II study
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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reports an interesting response rate for ETPF in patients with moderately
advanced SCC of the oropharynx. The schedule of ETPF evaluated in this study
cannot be recommended at this dosage.
Introduction
Cancer of the upper aerodigestive tract, predominantly
squamous cell carcinoma (SCC) of the oropharynx, is
the fifth most common malignancy and the seventh
leading cause of cancer death in France [1]. The major-
ity of diagnosed patients present locally advanced disease
invading underlying structures and/or spreading to
regional lymph nodes (stages III and IV). The survival
rates are relatively poor ranging from 30% to 60% at
5 years [2].
The standard treatment in moderately advanced disease
(i.e., resectable) includes surgery with appropriate adju-
vant therapy, and chemoradiotherapy in patients with
advanced disease (i.e., unresectable) [3]. Induction ther-
apy with cisplatin prior to definitive chemoradiotherapy
is still controversial [4, 5].
The most active induction chemotherapy regimen in
patients with unresectable SCC of the oropharynx is the
combination of 5-fluorouracil (5-FU), docetaxel, and cis-
platin (TPF) [6, 7]. However, an improvement in survival
comparing induction therapy followed by chemoradio-
therapy to direct chemoradiotherapy has not yet been
established.
An overexpression of the epidermal growth factor
receptor (EGFR) or any of its linked pathways occurs in
more than 90% of head and neck SCC [8]. Increased
EGFR protein expression or EGFR gene copy number
amplification are associated with poor prognosis [8–10],
radiation-resistance [11], locoregional treatment failure
[10], and increased rates of distant metastases [10, 12].
Monoclonal antibody cetuximab blocks ligand-induced
EGFR activation [13] and improves survival when used
concurrently in combination with radiotherapy in
locoregionally advanced disease [14] and cisplatin/5-FU-
based chemoradiotherapy in recurrent/metastatic setting
[15].
Human papillomavirus (HPV) type-16 (HPV16) infec-
tion has been associated with an increased risk of devel-
oping oropharyngeal cancer [16]. In contrary to the
HPV-negative tumors (primarily related to tobacco use
and alcohol consumption) [17, 18], an increasing
incidence and greater responsiveness to radiotherapy of
HPV-positive tumors have been reported [19–21]. The
potential role of anti-EGFR treatment in HPV16-positive
locally advanced oropharyngeal SCC cancer remains ques-
tionable [22].
The aim of this study was to evaluate the cetuximab-
TPF combination (ETPF) as induction therapy in treat-
ment of patients with locally advanced resectable SCC of
the oropharynx.
Materials and Methods
Study design
ECHO-07 (ClinicalTrials.gov #NCT00665392) was a pro-
spective multicenter single-arm open-label phase II study.
The protocol was approved by the National Security
Agency for Medicines and Health Products (ANSM,
France) and Ethics Committee of Groupe Hospitalier
Pitie-Salpetriere (Paris VI, France). All patients provided
written informed consent.
Patient eligibility criteria
Eligible patients were 18–75 years with previously
untreated, resectable AJCC/UICC TNM (American Joint
Committee on Cancer/Union Internationale Contre le
Cancer) stage III (T3/T1-2N1-2M0) to IVB (T4/T1-
3N3M0) SCC of the oropharynx [23]. Other eligibility
criteria included measurable or evaluable disease
(Response Evaluation Criteria in Solid Tumors [RECIST]
1.0), an Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 0–1, adequate laboratory
parameters (absolute neutrophil count (ANC) ≥1500/
mm3, platelet count ≥100,000/mm3, hemoglobin ≥9 g/dL,
creatinine <1.5-fold the upper limit of the normal (ULN)
value) and no uncontrolled cardiac or other disease.
Induction chemotherapy
Treatment consisted of cetuximab by intravenous (IV)
infusion over 1–2 h on days 1, 8, and 15 (loading dose of
400 mg/m2 on day 1, then 250 mg/m2 weekly) followed
the same day by docetaxel and cisplatin both given as a
1h IV infusion (at a 75 mg/m2 dose) and by 5-FU IV
infusion on days 1–5 (at a 750 mg/m2 dose per day).
Treatment was given every 3 weeks for a maximum of
three cycles. Pre- and concomitant medication consisted
of IV hydration and infusion of diphenhydramine hydro-
chloride and dexamethasone. A primary prophylaxis with
granulocyte colony stimulating factors (G-CSF) was
required.
722 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Induction Chemotherapy with Cetuximab B. Chibaudel et al.
Response assessments
Baseline assessment including medical history, physical
examination, otolaryngology evaluation with nasofibros-
copy, laboratory evaluation, histological diagnosis, and
computed tomography (CT) scan of the neck and chest
was performed within 3 weeks prior to induction therapy
initiation. During ETPF treatment, patients were assessed
for toxicity before each cycle of chemotherapy. The evalu-
ation of tumor response was assessed at 3 months from
inclusion and before local treatment using clinical exami-
nation and RECIST 1.0 criteria. After local treatment,
patients were evaluated regularly for 3 years.
The primary endpoint was clinical and radiological
complete response (crCR) rate of primary tumor. Second-
ary endpoints were clinical complete response (cCR) rate,
radiological complete response (rCR) rate, overall survival
(OS), progression-free survival (PFS), pathological com-
plete response (pCR), safety, and biomarkers analysis. OS
was defined as the time interval between patient inclusion
and death (all causes). Patients for whom death was not
recorded were censored at the date of last news. PFS was
defined as the time interval from inclusion to the first
local, regional and/or distant progressive disease (PD), or
death (all causes). Alive patients without PD were
censored at the date of last news.
Adverse events (AE) were collected during induction
treatment and follow-up visits. Toxicity evaluation was
carried out according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-
CTCAE, v3.0) scale.
Postinduction therapy
Local treatment with surgery or chemoradiotherapy after
induction therapy was not part of the study protocol and
was performed at investigator’s discretion.
Biomarkers analysis
For each patient, pretreatment formalin-fixed, paraffin-
embedded (FFPE) tumor tissue blocks or FFPE unstained
slides of primary tumor and cryopreserved tumor blocks
for molecular analysis of the EGFR pathway components
and HPV genotyping were required. The potential predic-
tive value of EGFR-related biomarkers for response to
ETPF induction therapy was evaluated by (1) EGFR gene
and EGFR ligands encoding genes expression analyses
(epidermal growth factor [EGF], transforming growth fac-
tor a [TGFa], amphiregulin [AREG], epiregulin [EREG],
heparin-binding EGF-like growth factor [HB-EGF], and
betacellulin [BTC]) performed by semiquantitative real-
time-PCR [24], (2) EGFRvIII gene expression analysis
performed according to Sok et al. [25], (3) EGFR-intron
1 polymorphism analysis according to Etienne-Grimaldi
et al. [26], and (4) EGFR gene copy-number assessed by
fluorescent in situ hybridization (FISH) using an EGFR/
CEN-7 FISH DNA/PNA probe (Dako, France). The high-
risk HPV16 genotype screen (by PCR) and quantification
of HPV16 viral DNA (by RT-PCR) were assessed.
Statistics
Given that a complete response (CR) rate ≤10% was
unsatisfactory, a CR rate ≥30% was expected. To test the
efficacy and safety of the treatment, 40 evaluable patients
were required to reach a power of 90% and at a signifi-
cance level 5% (a one-sided type I error). Assuming 5%
nonevaluable patients, a total of 42 patients had to be
enrolled. Analyses were performed on a modified intent-
to-treat (mITT) population (patients were considered
evaluable for tumor response if they had received at least
one dose of ETPF combination). Means (min-max) and
standard deviations (SDs) were used to describe continu-
ous variables; categorical variables were expressed in
terms of frequencies and percentages together with 95%
confidence intervals (CIs). Response rates and corre-
sponding 95% CIs were calculated using a binomial dis-
tribution. Survivals and median follow-up were estimated
using the Kaplan–Meier and reverse Kaplan–Meier meth-
ods, respectively. Stratified hazards ratios (HRs) were cal-
culated using the univariate Cox proportional hazard
model. Correlational research of EGFR-related biomarkers
and HPV status in tumors and blood samples obtained
prior and after induction therapy were done for explor-
atory purpose as planned in the study protocol. Statistical
analyses were performed using SAS 9.1 software (SAS
Institute Inc, Cary, NC).
Results
Patient characteristics
Between July 2008 and November 2011, 42 patients 42
patients were enrolled from nine centers (Table 1). Med-
ian age of patients was 56 years, with 81% males. The
majority of patients (79%) were ECOG PS 0, had a pri-
mary tumor located in the tonsil area (88%) and a stage
III disease (76%).
Induction treatment
Forty-one patients (mITT population) started induction
therapy (Fig. 1). One patient did not receive an intended
treatment due to investigator decision to replace cis-
platin by carboplatin and not to administer cetuximab.
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 723
B. Chibaudel et al. Induction Chemotherapy with Cetuximab
Thirty-one (76%) patients and 36 (88%) patients received
all nine planned doses of cetuximab and full three doses
of planned chemotherapy, respectively. Dose reduction of
cetuximab was required in two (5%) patients and in 10
(24%) patients for chemotherapy. Treatment had to be
stopped early in eight (19%) patients, mainly due to lim-
iting toxicity in five patients (diarrhea, febrile neutrope-
nia, neutropenia without fever, diarrhea with febrile
neutropenia, and skin toxicity), one toxic death (colonic
perforation), one acute pancreatitis, and one consent
withdrawal.
Tumor response
After ETPF, crCR of the primary tumor at 3 months was
observed in nine (22%) of 41 patients in the mITT popu-
lation (Table 2). Seventeen (41%) patients achieved cCR
and 14 (34%) had rCR. No disease progression occurred
during induction therapy. An objective response rate
(ORR) of 58% was observed.
PFS and overall survival
After a median follow-up of 23.9 months (95% CI,
15.4–28.6), median PFS was 37.6 months (95% CI,
19.1–NA), and median OS was not achieved. The 2-year
estimated PFS and OS rates were 63.6% and 82.4%
(standard error 8.2% and 6.6%), respectively (Fig. 2). Of
11 patients with PD, three progressed locally, four pro-
gressed in nodal sites, and three had metastatic recur-
rence.
Safety
The most frequent grade 3–4 toxicities in 41 treated
patients were neutropenia (39%), febrile neutropenia
(19%), diarrhea (10%), and stomatitis (12%) (Table 3).
All febrile neutropenia events occurred on days 8 or 15.
Acne-like skin reactions of any grade were observed in 18
(44%) patients. One (2%) toxic death occurred from che-
motherapy-induced colitis with colonic perforation
Table 1. Patient characteristics at baseline of the total study popula-
tion (n = 42).
Characteristics N %
Sex
Male 34 81.0
Female 8 19.0
Age in years, mean  SD 56.1  6.8
ECOG performance status
0 33 78.6
1 8 19.0
Missing 1 2.4
Grade of differentiation
Well 17 40.5
Moderate 18 42.9
Poor or undifferentiated 4 9.5
Missing 3 7.1
Primary tumor localization
Anterior 3 7.1
Lateral (tonsil area) 37 88.1
Posterior 1 2.4
Superior 1 2.4
Node involvement
Group I 1 2.4
Group IIa 31 73.8
Group IIb 9 21.4
Group III 10 23.8
Group IV 0 –
Group V 4 9.5
Group VI 0 –
T-stage
T2 13 31.0
T3 24 57.1
T4 5 11.9
N-stage
N0 5 11.9
N1 9 21.4
N2 27 64.3
N3 1 2.4
Staging
III 32 76.2
IV 10 23.8
Lip mobility
Normal 40 95.2
Decreased 2 4.8
Trismus
Yes 5 11.9
No 37 88.1
Creatinine clearance (mL/min)
<60 1 2.4
60–120 31 73.8
>120 8 19.1
Albuminemia (g/L)
<40 8 19.1
≥60 14 33.3
Missing 20 47.6
Life style risk factors
Alcohol 3 7.1
Tobacco 8 19.0
Table 1. Continued.
Characteristics N %
Alcohol + tobacco 25 59.5
None 6 14.3
HPV16 status
Positive 17 40.5
Negative 25 59.5
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group
performance status.
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during the first cycle of induction therapy. Of 18 serious
AE (SAE) reported by the investigators, four were consid-
ered to be cetuximab- and 13 chemotherapy-related toxic-
ities. None of them was unexpected.
Biomarkers analysis
Transcriptional analyses of FFPE from 38 patients were
performed. Univariate analysis identified EGFRvIII
mutation and EGFR amplification as predictive factors
significantly correlated with rCR (Table 4). Of 42 patients
tested for HPV16, 17 were HPV16-positive (40%)
(Table 5). A crCR was observed in four (24%) and five
(20%) patients with HPV-positive and HPV-negative
tumor, respectively.
Surgery
Neck dissection before postinduction therapy was per-
formed in seven patients who went onto chemoradiation
Figure 1. CONSORT diagram.
Table 2. Tumor response rates at 3 months in the modified intent-to-treat population (n = 41).
Tumor N (%) Node N (%) Tumor and node N (%)
Clinical response (cR)
Complete (cCR) 17 (41.5) 15 (36.6) 13 (31.7)
Incomplete 21 (51.2) 23 (56.1) 25 (61.0)
Progression 0 0 0
Not evaluable 3 (7.3) 3 (7.3) 3 (7.3)
Radiological response (rR)
Complete (rCR) 14 (34.1) 8 (19.5) 4 (9.8)
Major partial response (≥50%) 10 (24.4) 14 (34.1) 11 (26.8)
Minor partial response (<50%) 0 3 (7.3) 3 (7.3)
Stable disease 6 (14.6) 6 (14.6) 10 (24.4)
Progression 0 0 0
Not evaluable 11 (26.8) 10 (24.4) 13 (31.7)
Clinical and radiological response (crR)
Complete (crCR) 9 (22.0) 8 (19.5) 4 (9.8)
Incomplete 29 (70.7) 27 (65.8) 31 (75.6)
Progression 0 0 0
Not evaluable 3 (7.3) 6 (14.6) 6 (14.6)
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and in 22 patients who underwent surgery. Treatment
after primary tumor resection was performed in 22
patients (Fig. 1). Complete (R0) tumor resection was
achieved in 17 patients.
Chemoradiotherapy
After induction therapy, 36 patients received chemoradio-
therapy, either after surgical intervention (19 patients) or
without primary tumor resection (17 patients). A con-
comitant systemic therapy was carried out with cetuximab
(18 patients), platinum salt (14 patients), or both (three
patients). The median chemoradiation duration was
9.1 weeks (range, 1.0–13.1).
Pathological response
Of 22 patients with both primary tumor resection and
neck dissection, nine had a pCR of the primary tumor,
and six had a pCR of both the primary and node tumors.
Of the seven patients who underwent neck dissection, two
had a pCR.
A
B
Figure 2. Kaplan–Meier survival curves of progression-free survival (A) and overall survival (B). Thick line defines survival curve and thin line
denotes confidence boundaries placed around the true survival curve.
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Discussion
The ECHO-07 phase II study shows that addition of ce-
tuximab to the standard TPF induction regimen in
patients with locally advanced resectable stage III-IV SCC
of the oropharynx produces a crCR of 22%.
The major goals of induction chemotherapy are to
downsize the tumor, improve locoregional control, and
target distant metastases prior to definitive treatment.
TPF-based induction chemotherapy followed by chemora-
diotherapy has been shown to improve outcomes (time-
to-treatment failure, locoregional control) in patients with
advanced SCC of the oropharynx [6, 7, 27]. Despite the
potential benefits seen in these initial studies, recent trials,
DeCIDE and PARADIGM [4, 5], failed to show a survival
advantage with this treatment thus questioning the role of
induction chemotherapy.
The ETPF regimen was previously evaluated in 50
patients with unresectable SCC of the oropharynx [28].
In this phase II trial the ORR after four cycles of induc-
tion was 78%. In our study, induction ETPF was associ-
ated with a radiological tumor response (complete and
partial) of 58%, a low incidence of distant metastasis
(17%), and locoregional recurrence (7%). Given that the
tumor response definition differs across studies of
patients with SCC of the oropharynx, a comparison of
response rates with those given by others [4, 28, 29]
would be biased and misleading, therefore not accept-
able. The cCR in our study is about twofold higher than
crCR (41% vs. 22%). Such situation generates an urgent
need to standardize the current clinical endpoints defini-
tions and to evaluate more clinically relevant endpoints
(e.g., Health related quality of life measures). Defini-
tion for the Assessment of Time-to-event Endpoints in
CANcer trials (DATECAN) program to develop stan-
dardized definitions of commonly used endpoints,
enabling appropriate comparisons of future trials is cur-
rently ongoing [30].
A major concern of TPF induction treatment is a
high incidence of treatment-induced toxicity. In this
study, febrile neutropenia during ETPF induction was
reported in 19% of patients despite a systematic G-CSF
support required in the protocol. This rate is higher
than that reported by previous studies using TPF induc-
tion therapy (5–12%) [5–7, 31], but similar to prior
safety profiles when adding cetuximab to TPF [28]. This
may be explained by a weekly assessment of hematologi-
cal toxicities, rather than the addition of cetuximab to
TPF regimen. Moreover, removing 5-FU from ETPF
leads to a 10% rate of febrile neutropenia [32]. One
(2%) treatment-related death occurred during induction
therapy secondary to chemotherapy-induced colitis with
colonic perforation. Of note, only 22% of SAE were
considered to be cetuximab-related. 5-FU is currently a
substantial part of this three-drug induction regimen,
but its input remains debatable. A chemotherapy dou-
blet induction therapy with taxanes and platinum-salt
with cetuximab could be an appropriate approach to
improve therapeutic index while decreasing toxicity in
patients with SCC of the oropharynx [32–36]. Another
approach would be to use 5-FU with a shorter duration
of continuous infusion as performed in other cancers
[37]. To reduce associated toxicity during ETPF
administration, dose modifications of induction regimen
might be also considered. The modified TPF regimen
was shown to have similar efficacy with standard dose
TPF with an acceptable toxicity profile in gastric cancer
studies [38, 39].
Table 3. Safety evaluation carried out during induction treatment and follow-up in the modified intent-to-treat population (n = 41).
Adverse event
NCI-CTCAE v3.0 common toxicity criteria
Grade 0 N (%) Grade 1 N (%) Grade 2 N (%) Grade 3 N (%) Grade 4 N (%)
Hematologic toxicity
Neutropenia 22 (53.7) 0 2 (4.9) 6 (14.6) 10 (24.4)
Anemia 7 (17.1) 26 (63.4) 7 (17.1) 0 0
Thrombocytopenia 31 (75.6) 9 (21.9) 0 0 0
Febrile neutropenia 32 (78.1) 0 0 8 (19.5) 0
Nonhematologic toxicity
Nausea 25 (61.0) 8 (19.5) 7 (17.1) 1 (2.4) 0
Vomiting 28 (68.3) 8 (19.5) 4 (9.8) 1 (2.4) 0
Stomatitis 27 (65.8) 5 (12.2) 4 (9.8) 5 (12.2) 0
Diarrhea 14 (34.1) 12 (29.3) 11 (26.8) 3 (7.3) 1 (2.4)
Neuropathy 37 (90.2) 3 (7.3) 1 (2.4) 0 0
Acne-like skin reactions 23 (56.1) 9 (21.9) 7 (17.1) 2 (4.9) 0
Creatinine 32 (78.1) 7 (17.1) 2 (4.9) 0 0
NCI-CTC, National Cancer Institute Common Terminology Criteria for Adverse Events.
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We explored the potential value of the EGFR and its
ligands in predicting clinical response to ETPF treatment.
Although most markers correlated positively, only EGFR
amplification and EGFRvIII mutation were strongly asso-
ciated with CR by univariate analysis. Recent data
suggested that persistent signaling through c-MET activa-
tion in the setting of EGFR inhibition contributes to the
limited clinical responses to EGFR targeting in patients
with SCC of the oropharynx [40, 41]. Hence, future stud-
ies will need to investigate the relevance of cross talk
between EGFR and c-MET signaling and define whether
cosequential/sequential targeting of these oncogenic path-
ways may represent more effective therapy in this patient
population.
Table 4. Biomarker levels analysis according to tumor response in the patients for whom pretreatment formalin-fixed, paraffin-embedded tumor
tissue block, and cryopreserved tumor blocks were available (n = 38).
Response [95% CI]
All (N = 38)Complete (N = 9) Incomplete (N = 29)
EGFR
Median (min, max) 0.6 [0.1;2] 0.7 [0.1;89.6] 0.6 [0.1;89.6]
Mean (SD) 0.8 (0.7) 4.1 (17.1) 3.3 (14.8)
n 9 27 36
EGF
Median (min, max) 0.8 [0.1;3.3] 0.7 [0.1;76] 0.7 [0.1;76]
Mean (SD) 1.1 (1.1) 3.9 (14.5) 3.2 (12.5)
n 9 27 36
TGF a
Median (min, max) 4.2 [1.6;15.4] 4.6 [0.6;33] 4.4 [0.6;33]
Mean (SD) 5.3 (4.1) 8.2 (8.9) 7.5 (8)
n 9 27 36
HB-EGF
Median (min, max) 8.8 [0.6;28.9] 7.1 [0.7;66.9] 7.5 [0.6;66.9]
Mean (SD) 9.9 (9) 15.8 (17.7) 14.3 (16)
n 9 27 36
BTC
Median (min, max) 3.6 [0.9;8.6] 3.1 [0;68.3] 3.2 [0;68.3]
Mean (SD) 3.9 (2.6) 6.6 (12.9) 5.9 (11.2)
n 9 27 36
AREG
Median (min, max) 0.2 [0;3] 0.2 [0;92.9] 0.2 [0;92.9]
Mean (SD) 0.7 (1.1) 9.8 (24.8) 7.5 (21.8)
n 9 27 36
EREG
Median (min, max) 0 [0;0.9] 0 [0;9.5] 0 [0;9.5]
Mean (SD) 0.2 (0.3) 0.7 (1.9) 0.6 (1.7)
n 9 27 36
Allele 1 intron 1 CA repeats
Median (min, max) 16 [16;20] 16 [14;20] 16 [14;20]
Mean (SD) 16.7 (1.4) 16.4 (1.4) 16.5 (1.4)
n 9 27 36
Allele 2 intron 1 CA repeats
Median (min, max) 17 [16;20] 19 [15;22] 18 [15;22]
Mean (SD) 17.2 (1.4) 18.5 (2.2) 18.2 (2.1)
n 9 27 36
EGFRvIII mutation
No 5 (62.5%) 23 (88.5%) 28 (82.4%)
Yes 3 (37.5%) 3 (11.5%) 6 (17.7%)
EGFR amplification
No 3 (50%) 19 (82.6%) 22 (75.9%)
Yes 3 (50%) 4 (17.4%) 7 (24.1%)
EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; TGFa, transforming growth factor a; HB-EGF, heparin-binding EGF-like
growth factor; BTC, betacellulin; AREG, amphiregulin; EREG, epiregulin; AREG, amphiregulin; EREG, epiregulin; SD, standard deviation.
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HPV-positive patients with SCC of the oropharynx
have a more favorable outcome compared with HPV-
negative patients, however, this advantage can be
obscured in heavy smokers [22]. An increase in distant
metastases and tumor recurrence in patients with
advanced HPV-positive oropharyngeal cancer who
smoked tobacco was observed [42]. Moreover the risk
of cancer progression/death was shown to increase
directly as a function of pack-years/total number of
years of smoking, regardless of HPV status [18]. These
findings suggest that tobacco smoking may worsen
treatment response, disease control, and increase risk of
developing a second primary cancer. In our study, crCR
rate was comparable between HPV-positive patients
(24%) and patients with HPV-negative tumors (20%).
Only nine (21%) patients were nonsmokers, which
indicate that the majority of treated patients were at
increased risk for recurrence/death from disease. It will
therefore be of great importance to stratify patients for
HPV status and tobacco use in future trials to
discriminate those who are at high risk for treatment
failure.
In conclusion, ECHO-07 study reports an interesting
response rate for ETPF in patients with moderately
advanced SCC of the oropharynx. The dose levels of
the ETPF combination evaluated in this study cannot
be recommended. However, signs of clinical activity
seen in these patients suggest that its further evaluation
as induction therapy with optimal safety profile man-
agement is warranted.
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